证券代码：002603 证券简称：以岭药业 公告编号：2025-034 石家庄以岭药业股份有限公司 关于 2025 年半年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 石家庄以岭药业股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开 第八届董事会第十七次会议和第八届监事会第十二次会议，审议通过了《2025 年半年度利润分配预案》，该预案尚需提交公司 2025 年第一次临时股东大会审议。 现将相关情况公告如下： 一、本次利润分配预案的基本内容 财务报表实现归属于上市公司股东的净利润为 668,535,024.73 元，母公司报表实 现净利润为 430,517,933.00 元；截至 2025 年 6 月 30 日合并报表未分配利润为 与合并报表可分配利润数孰低的原则，截至 2025 年 6 月 30 日可供分配利润为 根据《公司法》《公司章程》及国家有关规定，为积极回报全体股东，与股 东分享公司经营发展的成果，结合公司股本现状、财务状况、未来发展前景等因 素，公司董事会提议 2025 年半年度利润分配预案为：以 202 ...

Core Insights - Yiling Pharmaceutical reported a revenue of 4,040,142,217.94 yuan for the first half of 2025, representing a year-on-year decline of 12.26% [1] - The net profit attributable to shareholders of the listed company was 668,535,024.73 yuan, showing a year-on-year increase of 26.03% [1] Financial Performance - The company's revenue decreased by 12.26% compared to the same period last year [1] - The net profit increased by 26.03% year-on-year, indicating improved profitability despite the revenue decline [1]

Core Viewpoint - Yiling Pharmaceutical has demonstrated significant growth in its financial performance, driven by high R&D investments and a strong pipeline of innovative traditional Chinese medicine products [1][2][3]. Financial Performance - In the first half of 2025, Yiling Pharmaceutical achieved a net profit of 669 million yuan, representing a year-on-year increase of 26.03% [1]. - Operating cash flow also saw a substantial increase, reaching 2.1497 billion yuan [1]. - R&D expenditure amounted to 399 million yuan, accounting for 9.87% of total revenue, positioning the company at a leading level within the industry [1]. R&D Investment - Since 2019, Yiling Pharmaceutical has invested over 5 billion yuan in R&D, emphasizing its commitment to technological innovation as a core driver of growth [2]. - The company has maintained a high R&D investment intensity, which has positioned it among the leaders in the traditional Chinese medicine sector [2]. Innovation and Product Pipeline - Yiling Pharmaceutical has received approvals for five new drugs over the past five years, showcasing a rapid pace of innovation in a sector typically characterized by long development cycles [3][4]. - The company currently holds 17 patented new drugs, indicating a fruitful period for its innovative drug pipeline [4]. Product Structure and Market Focus - The company has optimized its product business structure, with revenue from second-line patented products increasing by 53.18% during the reporting period [5]. - Yiling Pharmaceutical is focusing on high-quality niche categories within traditional Chinese medicine, reinforcing its long-term value proposition in the market [5]. Clinical Development and Future Prospects - As of the reporting period, Yiling Pharmaceutical has nine projects in clinical phases II and above, with seven classified as category 1.1 innovative traditional Chinese medicines [5]. - The company has submitted new drug applications for several products, with five additional varieties currently in phase II clinical research [5]. - The robust R&D pipeline covers major disease areas, including cardiovascular, respiratory, oncology, diabetes, neurological, and urological diseases, ensuring a steady output of innovative drugs [5]. Intellectual Property and International Expansion - Yiling Pharmaceutical holds 870 effective patents, including 484 for traditional Chinese medicine, providing a solid foundation for sustainable development [5]. - The high level of R&D investment supports the company's international expansion, with innovative patented traditional Chinese medicines registered in over 50 countries and regions globally [5].

（文章来源：证券日报） 证券日报网讯 8月27日晚间，以岭药业发布公告称，公司第八届监事会第十二次会议审议通过了《2025 年半年度利润分配预案》等多项议案。 ...

（文章来源：证券日报） 证券日报网讯 8月27日晚间，以岭药业发布公告称，公司第八届董事会第十七次会议审议通过了《关于 开立募集资金专项账户的议案》等多项议案。 ...

Group 1: Asset-Backed Securities (ABS) Market - In July 2025, the Asset-Backed Securities (ABS) market saw 153 new registrations with a total scale of 1440.49 billion yuan [1] - The top three ABS underlying assets by registration scale were financing lease receivables (313.66 billion yuan), accounts receivable (309.34 billion yuan), and small loan receivables (247.95 billion yuan) [1] - Six ABS registrations were related to infrastructure public REITs, amounting to 147.33 billion yuan [1] Group 2: Digital Printing Market - In the first half of 2025, China's digital industrial printer market generated revenue of 39.4 billion yuan, marking a year-on-year growth of 10.7% [2] - The large-format digital printing machine market experienced a decline of 2.8%, while the industrial digital textile printing machine market surged by 76.6% [2] - The digital packaging and labeling printing machine market saw a year-on-year increase of 9.3% [2] Group 3: Digital Publishing Industry - The digital publishing industry in China reached a record high revenue of 17,485.36 billion yuan in 2024, reflecting an 8.07% increase from the previous year [2] - The digitalization of books and periodicals showed steady growth, with significant revenue increases in online gaming, online education, and online animation sectors [2] Group 4: Insurance Sector - China Life Insurance reported a net profit of 40.931 billion yuan for the first half of 2025, representing a year-on-year growth of 6.9% [3] - The company's total revenue for the same period was 239.235 billion yuan, up by 2.1% year-on-year [3] - A cash dividend of 0.238 yuan per share (including tax) is proposed for all shareholders [3] Group 5: E-commerce and Food Delivery - Meituan's second-quarter revenue reached 91.84 billion yuan, showing an 11.7% year-on-year increase [4] - The adjusted net profit for the quarter was 1.49 billion yuan, down 89% year-on-year [4] - The core local business segment's revenue grew by 7.7% to 65.3 billion yuan, but operating profit fell significantly due to irrational competition [4] Group 6: Real Estate Investment Trusts (REITs) - JD Group plans to establish a REIT in Singapore with an asset value exceeding 1 billion USD, expected to be listed on the Singapore Exchange by next year [4] Group 7: Food Industry - Youyou Foods reported a net profit of 108 million yuan for the first half of 2025, a year-on-year increase of 42.47% [5] - The company's revenue for the same period was 771 million yuan, up by 45.59% [5] - A cash dividend of 2.3 yuan per 10 shares (including tax) is proposed for shareholders [5] Group 8: Technology Sector - Huasen Technology achieved a net profit of 1.889 billion yuan in the first half of 2025, reflecting a 46.3% year-on-year increase [6] - The company's revenue surged by 113.06% to 83.939 billion yuan [6] - Puxin Technology reported a net profit of 1.055 billion yuan, up 23.03% year-on-year [7] Group 9: Market Overview - The Shanghai Composite Index fell by 1.76% amid a market downturn, with over 4,700 stocks declining [8] - The total trading volume for the day reached 3.17 trillion yuan, an increase of 486.5 billion yuan from the previous trading day [8] - Key sectors showing strength included computing power and chip stocks, while real estate and consumer goods sectors faced declines [8]

Group 1 - Youyou Food achieved a net profit of 108 million yuan in the first half of 2025, a year-on-year increase of 42.47%, with a revenue of 771 million yuan, up 45.59% [1] - Keda achieved a net profit of 255 million yuan, a year-on-year increase of 16.49%, with a revenue of 2.163 billion yuan, up 14.35% [1] - North Navigation turned a profit with a net profit of 116 million yuan, achieving a revenue of 1.703 billion yuan, a year-on-year increase of 481.19% [1][2] Group 2 - China Satellite Communication reported a net profit of 181 million yuan, a year-on-year decrease of 55.59%, with a revenue of 1.221 billion yuan, up 6.33% [3] - Huqin Technology achieved a net profit of 1.889 billion yuan, a year-on-year increase of 46.3%, with a revenue of 83.939 billion yuan, up 113.06% [4] - Huasen Lithium reported a net loss of 72.739 million yuan, with a revenue of 350 million yuan, up 72.02% [4] Group 3 - Putailai achieved a net profit of 1.055 billion yuan, a year-on-year increase of 23.03%, with a revenue of 7.088 billion yuan, up 11.95% [5] - Suochen Technology reported a net loss of 45.698 million yuan, with a revenue of 57.351 million yuan, up 10.82% [5] - Canqin Technology achieved a net profit of 51.912 million yuan, a year-on-year increase of 51.94%, with a revenue of 287 million yuan, up 52.76% [6] Group 4 - Hengtong achieved a net profit of 99.3648 million yuan, a year-on-year increase of 38.86%, with a revenue of 669 million yuan, down 44.66% [6] - Sanan Optoelectronics reported a net profit of 176 million yuan, a year-on-year decrease of 4.24%, with a revenue of 8.987 billion yuan, up 17.03% [7] - New Dairy achieved a net profit of 397 million yuan, a year-on-year increase of 33.76%, with a revenue of 5.526 billion yuan, up 3.01% [8] Group 5 - Yiling Pharmaceutical achieved a net profit of 669 million yuan, a year-on-year increase of 26.03%, with a revenue of 4.040 billion yuan, down 12.26% [10] - Baosteel achieved a net profit of 4.879 billion yuan, a year-on-year increase of 7.36%, with a revenue of 151.372 billion yuan, down 7.28% [12] - Feikai Materials achieved a net profit of 217 million yuan, a year-on-year increase of 80.45%, with a revenue of 1.462 billion yuan, up 3.8% [13] Group 6 - Lier Chemical achieved a net profit of 271 million yuan, a year-on-year increase of 191.21%, with a revenue of 4.507 billion yuan, up 35.36% [15] - Shaanxi Coal achieved a net profit of 7.638 billion yuan, a year-on-year decrease of 31.18%, with a revenue of 779.83 billion yuan, down 14.19% [16] - Dongfang Materials reported a net profit of 654,400 yuan, a year-on-year decrease of 88.48%, with a revenue of 174 million yuan, down 5.06% [18] Group 7 - Blue Sky Bio achieved a net profit of 26.7163 million yuan, a year-on-year decrease of 8.98%, with a revenue of 652 million yuan, up 7.05% [19] - Shanghai Jiubai achieved a net profit of 23.7897 million yuan, a year-on-year increase of 0.24%, with a revenue of 45.0535 million yuan, down 1.09% [20] - Two Sides Needle reported a net loss of 5.0842 million yuan, with a revenue of 522 million yuan, up 1.02% [21] Group 8 - Shanghai Yashi achieved a net profit of 20.3263 million yuan, a year-on-year increase of 42.56%, with a revenue of 2.044 billion yuan, up 56.75% [23] - Bayi Steel reported a net loss of 697 million yuan, with a revenue of 8.733 billion yuan, down 6.73% [25] - Hongrun Construction plans to repurchase shares worth between 150 million and 300 million yuan [27] Group 9 - Kaile achieved a net profit of 10.9193 million yuan, a year-on-year increase of 280.42%, with a revenue of 137 million yuan, down 17.89% [28] - Jingda achieved a net profit of 306 million yuan, a year-on-year increase of 6.03%, with a revenue of 11.856 billion yuan, up 14.28% [29] - Blue Light Marker reported a net profit of 96.4427 million yuan, a year-on-year decrease of 47.33%, with a revenue of 32.36 billion yuan, up 4.87% [30] Group 10 - KOTAI Power achieved a net profit of 23.994 million yuan, a year-on-year increase of 35.52%, with a revenue of 711 million yuan, up 49.51% [33] - Bo Rui Data reported a net loss of 26.1918 million yuan, with a revenue of 70.1997 million yuan, up 5.19% [34] - Jiuzhoutong achieved a net profit of 1.446 billion yuan, a year-on-year increase of 19.7%, with a revenue of 81.106 billion yuan, up 5.10% [37] Group 11 - Aier Eye Hospital achieved a net profit of 2.051 billion yuan, a year-on-year increase of 0.05%, with a revenue of 11.507 billion yuan, up 9.12% [39] - Nandu Property achieved a net profit of 130 million yuan, a year-on-year increase of 532.87%, with a revenue of 914 million yuan, up 2.75% [41] - Weiyuan reported a net loss of 168 million yuan, with a revenue of 4.601 billion yuan, up 1.82% [42] Group 12 - Zhongke Chuangda achieved a net profit of 158 million yuan, a year-on-year increase of 51.84%, with a revenue of 3.299 billion yuan, up 37.44% [43] - Zhongjuxin reported a net profit of 8.1377 million yuan, a year-on-year decrease of 64.57%, with a revenue of 567 million yuan, up 20.40% [44] - Inspur Information achieved a net profit of 799 million yuan, a year-on-year increase of 34.87%, with a revenue of 80.192 billion yuan, up 90.05% [45] Group 13 - Shenghong Technology achieved a net profit of 2.143 billion yuan, a year-on-year increase of 366.89%, with a revenue of 9.031 billion yuan, up 86.00% [46] - Cambrian achieved a net profit of 1.038 billion yuan, turning a profit, with a revenue of 2.881 billion yuan, up 4347.82% [48] - Longteng Optoelectronics reported a net loss of 121 million yuan, with a revenue of 1.289 billion yuan, down 27.91% [49]

Core Viewpoint - Yiling Pharmaceutical has demonstrated strong resilience with a return to double-digit profit growth in the first half of 2025, achieving a net profit of 669 million yuan, a year-on-year increase of 26.03% [1] Product Dimension - Yiling Pharmaceutical has established a diversified pharmaceutical health industry structure, driven by three main sectors: patented traditional Chinese medicine, chemical drugs, and health industry [2] - The patented traditional Chinese medicine segment remains the profit cornerstone, contributing 1.963 billion yuan in revenue, accounting for 48.6% of total revenue, with a gross margin of 65.54% [2] - The chemical drug business is crucial for international market expansion, with significant progress in the development of innovative drugs and a well-structured product pipeline [2] - The health industry aligns with the "Healthy China 2030" strategy, focusing on modern health needs and creating a unique health product system [3] Theoretical Dimension - The theory of "Luo Disease" serves as a foundational pillar for Yiling Pharmaceutical's product development and is a core competitive advantage [4] - The company has developed numerous innovative traditional Chinese medicines under this theoretical framework, enhancing its academic standing and market competitiveness [4] R&D Dimension - Yiling Pharmaceutical invested 399 million yuan in R&D in the first half of 2025, representing 9.87% of its revenue, positioning it at a leading level within the industry [6] - The company has established various innovation platforms and a comprehensive drug integration innovation technology system to support future R&D efforts [6][7] - The company holds 870 valid patents, including 511 invention patents, which will bolster its future product offerings and market competitiveness [8]

石家庄以岭药业股份有限公司 第一章 总则 第一条 为了规范石家庄以岭药业股份有限公司（以下简称"公司"）信息 披露豁免与暂缓程序，依法及合规履行信息披露义务，保护投资者的合法权益， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司信息披露管 理办法》《上市公司信息披露暂缓与豁免管理规定》等有关法律、法规及《石家 庄以岭药业股份有限公司章程》（以下简称"《公司章程》"）的规定，结合公司实 际情况，制定本制度。 第六条 公司和其他信息披露义务人有保守国家秘密的义务，不得通过信 息披露、投资者互动问答、新闻发布、接受采访等任何形式泄露国家秘密，不得 以信息涉密为名进行业务宣传。 第三条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平 地披露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者，不得 实施内幕交易、操纵市场等违法行为。 第四条 公司和其他信息披露义务人应当审慎确定信息披露豁免、暂缓事 项，履行内部审核程序后实施。 豁免、暂缓事项的范围原则上应当与公司股票首次在证券交易所上市时保持 一致，在上市后拟增加豁免、暂缓披露事项的，应当有确实充分的证据。 信息披露豁免与暂缓管理制度 ...

格隆汇8月27日丨以岭药业（维权）(002603.SZ)公布2025年半年度报告，上半年公司实现营业收入40.40 亿元，同比下降12.26%；归属于上市公司股东的净利润6.69亿元，同比增长26.03%；归属于上市公司股 东的扣除非经常性损益的净利润6.41亿元，同比增长27.08%；基本每股收益0.4002元；拟向全体股东每 10股派发现金红利3.00元(含税)。 ...